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Abstract
Rationale:Whether pharmacological therapy alters decline in FEV1
in chronic obstructive pulmonary disease remains controversial.
Because pharmacotherapy improves health status, exacerbation rate,
and symptoms, it may be unethical to complete placebo-controlled
long-term studies aimed at modifying FEV1 decline.
Objectives:We conducted a systematic review of placebo-
controlled pharmacological trials lasting>1 year to address the
question of whether therapy alters FEV1 decline.
Methods: A literature search for randomized trials that included
repeated spirometry with at least one active and one placebo armwas
conducted. Articles were excluded if study duration was,1 year,,3
spirometric measurements, or,100 subjects per arm. Study design
was assessed using the Jadad score. To combine studies and find the
estimated effect, we used random effects methodology to account for
both within-study and between-study variation.
Measurements and Main Results: There were 33,051 patients
in the analysis (active component, n= 21,941; placebo, n= 11,110
in nine studies). The active treatment arms demonstrated a
5.0 ml/yr reduction (95% confidence interval, 0.8–9.1 ml/yr;
P, 0.001) in the rate of FEV1 decline compared with the
placebo arms. The relative FEV1 differences between active
and placebo arms were within the range of differences reported
for health status and for the exacerbation rate in the same
studies.
Conclusions: In chronic obstructive pulmonary disease,
pharmacotherapy ameliorates rate of lung function decline. The
relative benefit observed is within the range of those reported for
health status and exacerbations in the same studies. Guidelines
should be adjusted according to these findings.
Keywords: chronic obstructive pulmonary disease; lung
function decline; forced expiratory volume; systematic review;
spirometry
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Although the spirometer was first used to
determine lung function in 1846, it was not
until the late 1950s that the FEV1 of an FVC
maneuver was proposed as a test to detect
the presence of airflow limitation (1).
Fletcher and coworkers assessed the change
of FEV1 over time in men who smoked,
linking the rapid decline of that variable to
progression of what is now recognized as
chronic obstructive pulmonary disease
(COPD) (2). The same authors, and
subsequent observational and
interventional trials, have shown that
cessation of smoking results in near
normalization of the rate of FEV1 decline
and thus could change the progression of
disease (3, 4). This remains the gold
standard to evaluate the evolution of COPD
over time.
Pharmacological trials conducted more
than 30 years ago using short-acting
bronchodilators or inhaled glucocorticoids
failed to demonstrate a statistically
significantly slower rate of FEV1 decline
compared with placebo in their intention-
to-treat populations (3, 5, 6). Based on
these neutral results, the dogma became
that the only therapy to alter COPD
progression was smoking cessation.
Regrettably, this nihilism has negatively
affected the public view of this disease and
reduced the interest in alternative
therapeutic approaches to COPD.
Recent studies provide information
that may help explain the lack of effect of
pharmacotherapy in these early trials. First,
the mean rate of FEV1 decline in patients
with COPD is lower (4, 7, 8) than that
initially reported by Fletcher and
colleagues. Second, close to half of subjects
with COPD do not have a rate of decline
that is steeper than that of healthy smokers
and nonsmokers without COPD (9).
Therefore, studies evaluating the average
change of FEV1 of the enrolled subjects
have been affected by the inclusion of
“normal decliners” that diminish the power
to observe an effect of the therapy. Third,
the older pharmacological agents used in
some of those studies have a short duration
of action, and most studies have not been
long enough to determine changes in the
FEV1 for a chronic disease that by
definition has a natural history lasting
many years.
Fortunately, there have been several
randomized trials conducted over recent
decades that enrolled a large number of
patients, included different long-acting
pharmacological agents, have lasted long
enough to test the effect of those agents on
average FEV1, and have included a placebo
comparator arm (10–12). Because of the
favorable impact of those therapies on
exacerbations, health status, and dyspnea, it
is unlikely that such studies using a placebo
arm will be conducted again as it could be
considered unethical to maintain
symptomatic patients with COPD on
placebo over a long enough time to
determine lung function change. In view of
this, and prompted by the positive results
on FEV1 decline in some of the individual
trials, we have conducted a systematic
review to evaluate the effectiveness of
pharmacotherapy on rate of FEV1 decline
in COPD trials lasting at least 1 year.
Methods
This systematic review is reported in
accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-
Analyses Statement (13) (Figure 1). A
comprehensive literature search for
randomized controlled trials (RCTs) lasting
at least 1 year and enrolling at least
100 patients per arm that included
measurement of spirometry as one of the
outcomes and at least one arm of an active
medication and one with placebo were
reviewed. Three authors (B.R.C., J.Y., and
H.Q.) independently checked the relevant
RCTs found from the literature. RCTs were
selected in agreement with the previously
mentioned criteria, and any difference in
opinion about eligibility was resolved by
consensus.
Study Selection
A systematic review of the literature was
conducted to identify clinical trials designed
to assess the effect of an intervention on
decline in FEV1 in patients with COPD
(Figure 1). Initially, a PubMed search
conducted through 2017 identified relevant
articles based on the following search
criteria: COPD diagnosis, decline in lung
function/FEV1, and study design (Table E1
in the online supplement). Additional
records published after the initial search
date until December 2019 were identified.
The resulting articles underwent a three-
step review to identify the studies relevant
for this analysis. There was an initial
screening of each title and abstract to
confirm whether data were relevant for this
research objective. The full text of articles
selected in the initial review were assessed
and excluded if they met any of the
following criteria: nonpertinent publication
type, duration of study less than 1 year,
fewer than three spirometry assessments,
fewer than 100 subjects per arm,
non–physician-diagnosed COPD, lack of
quantitative data, or failure to present FEV1
At a Glance Commentary
Scientific Knowledge on the
Subject: The Global Initiative for
Chronic Obstructive Lung Disease
(GOLD) states that in patients with
chronic obstructive pulmonary disease,
pharmacotherapy is effective in
reducing symptoms and exacerbations
and improving quality of life and
exercise endurance but that there is no
conclusive evidence that it modifies the
long-term decline in lung function.
GOLD also states that trials should be
specifically designed to test whether
pharmacotherapy can achieve such
an effect. Given the benefit that
medications provide to patients with
chronic obstructive pulmonary disease
in important outcomes such as
exacerbations, dyspnea, and health
status, it is unethical to subject
symptomatic patients with chronic
obstructive pulmonary disease to long-
term trials using a placebo control.
Owing to these constraints, we
completed a systematic review of
placebo-controlled pharmacological
trials lasting longer than 1 year to
answer the question of whether FEV1
decline can be ameliorated by
pharmacological therapy.
What This Study Adds to the Field:
This systematic review shows that
pharmacotherapy is effective in
altering rate of lung function decline.
The observed difference of 5 ml per
year between active medications and
placebo corresponds to a benefit that is
similar to the annual differences
reported for outcomes (health status
and exacerbation rates) that are
considered to be improved by the same
agents, in the same studies here
evaluated. Current guidelines should
be adjusted to reflect these findings.
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decline in ml/yr as well as the variance
for the FEV1. Additional exclusions
occurred during the data extraction phase
if applicable information was not
available.
Outcomes
The main outcome of interest was the
difference in rate of FEV1 decline in ml/yr
between the active pharmacological therapy
compared with placebo. In a secondary
analysis, we explored differences between
individual medication components and
placebo on the same outcome. We also
present the differences in exacerbation rates
and St. George’s Respiratory Questionnaire
(SGRQ) scores between the active and
the placebo arms in the same studies, to
help interpret the relative benefit of the
absolute treatment difference observed in
FEV1.
Quality Score and Risk of Bias
Assessment
The Jadad score, with a scale of 1 to 5 (with 5
being highest), was used to assess the quality
of the papers concerning the likelihood of
bias related with randomization, double
blinding, withdrawals, and dropouts (14).
Statistical Analysis
To combine the studies to find the overall
estimated effect, we used random effects
methodology to account for both within-
study and between-study variation (15). The
therapies were compared and the treatment
differences and 95% confidence intervals
(CIs) were presented in a Forest plot. We
performed four separate post hoc analyses
to investigate the effect of the different
classes of therapies on the rate of decline in
FEV1 (ml/yr). These were active versus
nonactive, excluding the BRONCUS
(Bronchitis Randomized on NAC Cost-



































Full-text articles excluded: n=234
- No drug intervention aimed at reducing FEV1 decline (n=64)
- Study population also included non-COPD subjects; data not
  stratified for COPD (n=32)
- No decline in FEV1 reported (n=27)
- Review (systematic review: n=13; nonsystematic review: n=4)
- Too small sample size (n=15)
- Follow-up <1 years (n=14)
- FEV1 not used as outcome measure (n=13)
- Data not stratified for intervention (n=12)
- Duplicate studies (n=9)
- Nonpertinent publication type (model: n=2; guideline: n=1;
   other: n=4)
- Lack of (clear) information on spirometry measure (n=4)
- Factor not relevant for objective 2 (n=3)
- Figure only (n=3)
- Size (less than 100 patients per arm) (n=3)
- Study population not clear (n=2)
- Meta-analysis/pooled analysis (n=2)
- Other (included data of treatment group only: n=1; no useful
  results: n=2; phase II study: n=1; unclear method section: n=1;
  COPD self-reported: n=1): n=1 results presented as median in





Figure 1. Flow diagram of the systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
COPD=chronic obstructive pulmonary disease.
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oral agent N-acetylcysteine as the active
medication; inhaled corticosteroid (ICS)
versus non-ICS; and long-acting
bronchodilators (LABDs), either long-
acting muscarinic antagonist or long-acting
beta adrenergic bronchodilators, versus
arms without bronchodilators (non-
LABD); in the UPLIFT (Understanding
Potential Long-Term Impacts on Function
with Tiotropium) study, 60% of patients in
both arms were receiving long-acting
b-adrenergic agents. No adjustments were
made for multiplicity. To investigate the
effect of ICS versus non-ICS, in studies with
more than one ICS arm, these ICS arms
were combined (e.g., in SUMMIT [Study to
Understand Mortality and Morbidity], we
pooled fluticasone furoate [FF] and
FF/vilanterol to be in the ICS arm).
Means and SEs were extracted from the
publications, and where necessary, 95% CIs
were used to derive SEs. We calculated the
Q statistic and from this the I2 statistics to
quantify the heterogeneity. SAS version 9.4
(SAS Institute) was used for all analyses.
Results
Study Characteristics
A total of 33,051 patients with COPD were
included in the analysis (active component,
n= 21,941; placebo, n= 11,110) selected
from nine published studies (3, 6, 11,
16–21). One study used tiotropium, one
used fluticasone furoate/vilanterol
(FF/vilanterol) and the components, one
fluticasone propionate/salmeterol and
the components, one used fluticasone
propionate alone, one used budesonide,
one used triamcinolone, one used
N-acetylcysteine, and one used ipratropium
bromide. All studies were published
between 1994 and 2018, and relevant
patient demographics and study
characteristics are summarized in Table 1.
The mean Jadad score for the nine studies
was 4.8. All trials were randomized and
double-blind and with period of treatment
and observation that ranged from
40 months to 5 years.
Impact of Pharmacotherapy on FEV1
Decline
Table 2 shows the values of FEV1 decline
for the placebo and active arms in each of
the individual studies included in this
review. As shown in Figure 2, the overall
active treatment arms demonstrated a 5.0-
ml/yr reduction (95% CI, 0.8–9.1 ml/yr;
P, 0.001) in the rate of FEV1 decline
compared with the placebo arms. Figure E1
shows the results of the same analysis,
excluding the BRONCUS study because it
used the oral agent N-acetylcysteine. This
analysis demonstrated a larger difference in
favor of all active components compared
with placebo of 5.6 ml/yr (95% CI, 1.3–9.8).
Table E2 shows the effects of therapy on
exacerbations and SGRQ for all treatment
arms in the studies included in this analysis.
Figure 3A shows that the difference
between the studies with an active ICS or
ICS/bronchodilator-containing arms and
placebo was 7.3 ml/yr (95% CI, 4.1 to 10.5),
whereas Figure 3B shows that the difference
between LABD-containing arms against
placebo was 4.9 ml/yr (95% CI, 20.8 to
10.6). Of note, in the UPLIFT trial, 60% of
the patients randomized to placebo were
already taking long-acting b-agonists.
Discussion
This systematic review shows that
pharmacological therapy modifies disease
progression as expressed by the rate of
decline in FEV1 in patients with COPD.
Although the yearly difference may seem
small in absolute numbers, its significance
over time is important in a disease in which
progression is measured in decades.
The most recent Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
report states that pharmacotherapy is
effective in reducing symptoms and
exacerbations and improving quality of life
and exercise endurance, but there is no
conclusive evidence that it modifies the
long-term decline in lung function (22), and
this view is reflected in the most recent
guidance on the pharmacological treatment
of COPD published by the American
Thoracic Society (23). Based on the
observation that some post hoc analyses of
large studies had suggested an effect of ICS
on rate of FEV1 decline, the GOLD
document states that trials should be
specifically designed to test whether ICS
can achieve such an effect. However, given
the benefit that inhaled medications
provide patients with COPD in outcomes
such as exacerbations, dyspnea, and health
status, it would be unethical to subject
symptomatic patients with COPD to trials
that include a placebo-controlled arm for
studies that may last over several years.
The first consideration worth
addressing from the results is the
significance of the average difference of 5.0
ml/yr in FEV1 between active medications
and placebo. A good starting point is to
compare this difference with the changes
reported in the same studies (where the
same issues of differential dropout and
patient selection apply) for other patient-
related outcomes, such as health status and
exacerbations, which have led to the
acceptance of pharmacotherapy as being
effective in COPD. This comparison is
difficult because the units used to measure
the different outcomes differ, and their
interpretation may be difficult to judge.
With all these limitations, it is interesting to
note that the differential benefit observed
for FEV1 is within the range of the benefits
reported for health status and for
exacerbation rate shown in Table E2.
Indeed, although a relative decrease of
exacerbation in the same studies ranges
from 3% to 43%, and that of the SGRQ
ranges between 1 and 3 units in a scale
from 0 to 100, the FEV1 difference ranges
from 4% to 43% of the rate of FEV1 decline
observed in the placebo arm in those
studies. No comparison was made with
exercise endurance in that table because
this was not reported in any of the studies
analyzed. However, several studies
evaluating the benefit of pharmacological
agents on exercise endurance compared
with placebo using a constant load
cardiopulmonary exercise test show a
proportional increase that ranges from 3%
to 10% in favor of the active medication
(24, 25).
It is important to note that the FEV1
decline benefit observed in the studies
included may underestimate the true effect
of the medications on many patients
because close to half of patients who are
diagnosed as having COPD in the sixth
decade do so without a rapid decline in
lung function and thus are unlikely to
normalize an already normal rate of lung
function decline (9). Although one of the
studies included (26) suggested that blood
eosinophil level might influence the
beneficial effect of FEV1 progression, the
lack of this variable in the larger data set
precludes any firm conclusion on this
potential relationship. As seen in Table 1, in
all studies included, the dropout rate was
larger in the placebo compared with the
active arm. Patients who drop out of
pharmacological trials tend to be sicker,
ORIGINAL ARTICLE
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with worse outcomes in all variables tested,
whereas the remaining patients in the
placebo arm are usually healthier, therefore
tending to bring all variables to the
projected mean change for that variable
(27, 28), an effect that may be partially
adjusted by the use of the random effects
models, as was done in most of those
studies. In addition, the mean age of
patients recruited into the studies included
was approximately 64 years, when most of
the course of COPD has been run and
modification of clinical outcomes is more
difficult to obtain. This is important
because the age at which therapy is initiated
influences the degree of response. Indeed,
the study by Morice and colleagues (29)
showed that in 356 patients younger than
50 years in the UPLIFT study, there was a
mean decline in post-bronchodilator FEV1
that was 58 ml/yr for placebo compared
with 38 ml/yr for tiotropium, a 20-ml/yr
difference. This suggests that if therapy was
initiated earlier (i.e., at 50 yr), the putative
100-ml minimal important difference
threshold could be reached in 5 years. It is
also likely that response to therapy varies
and that specific subgroups may experience
even better outcomes. That this seems to be
the case is suggested by the larger benefit
observed in patients with moderate
airflow limitation (GOLD 2) compared
with severe and very severe obstruction
(GOLD 3 and 4) in those studies in which
either by study design or by post hoc
analysis the response was evaluated in
relation to airflow limitation severity (19,
30). Finally, the true difference between the
absolute improvement in FEV1 between
active treatment and placebo is larger
because all pharmacological therapies
include a bronchodilator effect that
averages close to 100 ml for the drugs
studied.
Data for individual components could
only be completed for ICS, ICS-containing
combinations, and LABD because those
were the only studies with enough subject
numbers to provide meaningful data. As can
be seen in Figure 3, the difference was
statistically significant for the ICS-
containing arms compared with placebo,
and although not significant for LABD, it
may have reached significance if there were
more long-term studies for these drugs and
if 60% of the patients in the UPLIFT study
using tiotropium had not been on long-
acting b-adrenergic agents. The exclusion
of the only study using the oral medication
N-acetylcysteine resulted in an average





































Overall Active Therapy 5.0 mL/year (95% CI 0.8, 9.1)
–30 –25 –20 –15 –10 –5 0 5 10 15 20 25 30 35 40
Figure 2. Effect of all active therapies on the rate of decline in FEV1. The center of the diamond indicates the point estimate and the width is the 95% CI.
BRONCUS=Bronchitis Randomized on NAC Cost-Utility Study; CI = confidence interval; COPD=chronic obstructive pulmonary disease;
ISOLDE= Inhaled Steroids in Obstructive Lung Disease in Europe; LHS=Lung Health Study; LHS2=Lung Health Study 2; SUMMIT=Study to
Understand Mortality and Morbidity; TORCH=Toward a Revolution in COPD Health; UPLIFT=Understanding Potential Long-Term Impacts on Function
with Tiotropium.
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reduction of 5.9 ml/yr in the rate of FEV1
decline compared with the placebo arms
(Figure E1).
We cannot address the reasons why the
different treatments might influence the rate
of decline of FEV1, although as we illustrate,
treatment reduces exacerbation rates, which
are associated with lung function decline
(8, 31). Recent data have shown that
maximizing the therapy that is usually
given to patients with COPD and more
severe disease and exacerbations can reduce
the risk of these events and of dying (32,
33); these findings are consistent with this
complementary evidence from the
published literature.
This systematic review is useful because
it addressed one single research question,
used studies with a large number of patients,
had a high-quality control of the primary
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SUMMIT Composite LABD Arm
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LABD Therapy 4.9 mL/year (95% Cl –0.8, 10.6)
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Difference vs. Non-LABD, mL/year
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B
Figure 3. (A) Effect of ICS-containing therapies on the rate of decline in FEV1. The center of the diamond indicates the point estimate and the width is the
95% confidence interval (CI). (B) Effect of inhaled LABD therapy on the rate of decline in FEV1. The center of the diamond indicates the point estimate and
the width is the 95% CI. COPD=chronic obstructive pulmonary disease; ICS= inhaled corticosteroid; ISOLDE= Inhaled Steroids in Obstructive Lung
Disease in Europe; LABD= long-acting bronchodilator; LHS2=Lung Health Study 2; SUMMIT=Study to Understand Mortality and Morbidity; TORCH=Toward
a Revolution in COPD Health; UPLIFT=Understanding Potential Long-Term Impacts on Function with Tiotropium.
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a long enough period of time to provide an
answer to the research question. It also
addresses a very important need to
modify disease progression, for which
there will unlikely be a prospective study,
given the ethical implications for its
implementation. However, there are
limitations that are inherent to any review.
Some studies cannot be included because
they do not meet the selection criteria.
One such study, European Respiratory
Society Study on Chronic Obstructive
Pulmonary Disease (EUROSCOPE),
deserves a special comment (5). It
specifically addressed the question posed
here, comparing the FEV1 decline over 3
years between inhaled budesonide and
placebo. However, the study could not be
included because the results were reported
as median values without their variance.
However, in that study, the FEV1 decline
in the active arm was 57 ml/yr compared
with 69 ml/yr in placebo-treated patients,
in agreement with our overall results.
Finally, reviews cannot provide adequate
comparisons of the treatment effects of
the different medications. However, the CI
in the larger studies provides a good
approximation to the average effect of each
of the components included in the analysis.
Conclusions
Our analyses show that pharmacotherapy
is effective in altering rate of lung
function decline and that the yearly
absolute difference observed is similar to
the treatment difference reported for
clinical outcome such as health status
and exacerbations. Current guidelines
should be adjusted to reflect these findings,
and future studies should be directed
to evaluate the potential benefits in patients
likely to benefit, such as those with rapid
lung function decline. n
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